Affiliation: Duke University Medical Center
- Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021Ross E McKinney
Department of Pediatrics, Duke University Medical Center, Box 3461, Durham, NC 27710, USA
Pediatrics 120:e416-23. 2007..Compliance with complex antiretroviral therapy regimens is a problem for HIV-1-infected children and their families. Simple, safe, and effective regimens are important for long-term therapeutic success...
- Should an institution that has commercial rights in a new drug or device be allowed to evaluate the technology?Ross McKinney
Duke University School of Medicine, Durham, North Carolina, USA
PLoS Med 2:e9. 2005..Although this financial incentive can stimulate academic researchers to discover new drugs and devices, there is concern that the possibility of monetary reward could distort investigators' objectivity...
- Congress, the FDA, and the fair development of new medications for childrenRoss E McKinney
Department of Pediatrics, Division of Infectious Diseases, Duke University School of Medicine, Durham, NC 27710, USA
Pediatrics 112:669-70. 2003
- Newer treatments for HIV in childrenRoss E McKinney
Departmentof Pedicatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
Curr Opin Pediatr 16:76-9. 2004..Several new antiretroviral agents have been introduced into pediatric and adult use. This review will summarize information about these new agents and other recent advances in the care of HIV-infected children...
- Growth as a part of the composite endpoint in paediatric antiretroviral clinical trialsDaniel K Benjamin
Department of Pediatrics, Duke University, Durham, NC, USA
J Antimicrob Chemother 54:701-3. 2004....
- Growth, survival and viral load in symptomatic childhood human immunodeficiency virus infectionCaroline J Chantry
Department of Pediatrics, University of California Davis Medical Center, Sacramento 95817, USA
Pediatr Infect Dis J 22:1033-9. 2003..The relationships among weight and height growth, viral load and survival in HIV-infected children remain unclear...
- Genetic influence of CCR5, CCR2, and SDF1 variants on human immunodeficiency virus 1 (HIV-1)-related disease progression and neurological impairment, in children with symptomatic HIV-1 infectionKumud K Singh
Department of Pediatrics, Division of Infectious Diseases, University of California, San Diego, La Jolla, California 92093 0672, USA
J Infect Dis 188:1461-72. 2003..These data suggest that, in children, host genetics plays an important role in HIV-1-related disease progression and neurological impairment...
- A comparison of height and weight velocity as a part of the composite endpoint in pediatric HIVDaniel K Benjamin
Duke Clinical Research Institute and the Department of Pediatrics, Duke University, Durham, North Carolina, USA
AIDS 17:2331-6. 2003..However, WAZ and height velocity (HAZ) have not been critically compared for their utility as part of the composite endpoint...
- Prevalence of chemokine and chemokine receptor polymorphisms in seroprevalent children with symptomatic HIV-1 infection in the United StatesKumud K Singh
Department of Pediatrics, Division of Infectious Diseases, University of California at San Diego, La Jolla 92093 0672, USA
J Acquir Immune Defic Syndr 35:309-13. 2004..These analyses show that the distribution of chemokine receptor and chemokine genetic polymorphisms varies significantly across race/ethnicity subgroups of HIV-1-infected children in the United States...
- Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and childrenEdmund V Capparelli
University of California, San Diego, School of Medicine, La Jolla, California, USA
J Clin Pharmacol 43:133-40. 2003..It was concluded that ZDV oral clearance is reduced in infants compared to older children. This lower clearance leads to higher ZDV exposure in infants and contributes to increased hematologic toxicity...
- Shooting at a moving target: natural history studies and the rapidly improving state of anti-HIV treatmentRoss E McKinney
J Pediatr 141:301-2. 2002
- North Carolina Collaborative PPRU NetworkRoss McKinney; Fiscal Year: 2004..6) To train physicians and pharmacologists in clinical and developmental pharmacology: the centerpiece will be a 3-year pediatric pharmacology fellowship. Drs. Brouwer and Lindley (UNC) will lead this program. ..
- Integrated Human Research Subjects Protection ProjectRoss McKinney; Fiscal Year: 2003..abstract_text> ..